CUDC-101 was the first multitarget epi-drug to be trialled (ClinicalTrial.gov identifier: NCT01171924), which targets HDAC, epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), in patients with advanced head and neck, breast, gastric, liver and lung cancers. This evidence concerns the gene EGFR and lung cancer.